The Medicines Company

Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?
Motley Fool
Novartis
M&A
AveXis
Zolgensma
Endocyte
Pluvicto
The Medicines Company
Levqio
Flag link:
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire
Pharmacquired: Splashy deals belie a shallow pool of heart drugs left to acquire
BioPharma Dive
M&A
cardiology
Bristol-Myers Squibb
MyoKardia
Novartis
The Medicines Company
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
Novartis buys Medicines Co. in $9.7B bet on cholesterol drug
Novartis buys Medicines Co. in $9.7B bet on cholesterol drug
Biopharma Dive
Novartis
The Medicines Company
M&A
Flag link:
Amidst Novartis Takeover Rumors, The Medicines Company Announces Positive Cholesterol Data
Amidst Novartis Takeover Rumors, The Medicines Company Announces Positive Cholesterol Data
BioSpace
The Medicines Company
Novartis
M&A
inclisiran
clinical trials
Flag link:
Novartis eyes Medicines Co to boost cardio franchise - report
Novartis eyes Medicines Co to boost cardio franchise - report
Yahoo/Reuters
Novartis
The Medicines Company
cardiovascular disease
M&A
Flag link:
AHA: MedCo's PCSK9 rival inclisiran hits LDL
AHA: MedCo's PCSK9 rival inclisiran hits LDL
Fierce Biotech
AHA
The Medicines Company
inclisiran
Flag link:
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
Yahoo/Benzinga
AHA
The Medicines Company
Intrexon
Alnylam
Pieris
Roche
Flag link:
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
Xconomy
The Medicines Company
clinical trials
inclisiran
cholesterol
Flag link:
Medicines Co. awaits its date with destiny
Medicines Co. awaits its date with destiny
Biopharma Dive
The Medicines Company
clinical trials
inclisiran
Flag link:
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Forbes
The Medicines Company
Amgen
Sanofi
Regeneron
inclisiran
PCSK9 inhibitors
Flag link:
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
Xconomy
The Medicines Company
Alnylam
inclisiran
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
biotech
Achillion
Sesen Bio
The Medicines Company
Amgen
Daiichi Sankyo
earnings
Flag link:
Here's Why Shares of The Medicines Company Sank 14.5% Today
Here's Why Shares of The Medicines Company Sank 14.5% Today
Motley Fool
The Medicines Company
Flag link:
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
Xconomy
Qpex Biopharma
The Medicines Company
drug-resistant bacteria
Flag link:
The Medicines Co., in pivot to pipeline PCSK9 med, secures $270M asset sale
The Medicines Co., in pivot to pipeline PCSK9 med, secures $270M asset sale
Fierce Pharma
The Medicines Company
PCSK9 inhibitors
inclisiran
Vabomere
Flag link:
The Medicines Company PCSK9 Inhibitor Strategy: More Heart Patients Via Lower Pricing
The Medicines Company PCSK9 Inhibitor Strategy: More Heart Patients Via Lower Pricing
Forbes
The Medicines Company
PCSK9 inhibitors
drug pricing
inclisiran
Flag link:
New antibiotic therapies: what future?
New antibiotic therapies: what future?
GoinPharma
antibiotics
Merck
Paratek
Tetraphase Pharmaceuticals
Motif Biosciences
The Medicines Company
Flag link:
Data in hand, The Medicines Co. speeds PCSK9 plans
Data in hand, The Medicines Co. speeds PCSK9 plans
BioPharma Dive
The Medicines Company
PCSK9 inhibitors
inclisiran
Flag link:
Despite Promising Early Data, The New Cholesterol Lowering Drug - PCSK9si - Has Significant Hurdles
Despite Promising Early Data, The New Cholesterol Lowering Drug - PCSK9si - Has Significant Hurdles
Forbes
PCSK9 inhibitors
PCSK9si
The Medicines Company
Flag link:

Pages